Improving outcomes for women diagnosed with early breast cancer through adherence to adjuvant endocrine therapy: the feasibility study

ewcastle upon Tyne Hospitals NHS Foundation Trust0 个研究点目标入组 90 人开始时间: 2022年8月12日最近更新: 2023年8月7日

适应症

试验速览

暂无简介。

•Sub-study 1
•The following patients will be eligible:
•1. Aged 18 years old and over
•3. Diagnosis of ER-positive invasive breast cancer
•4. Medium or high risk of recurrence, defined as one of the following:
•4.1. T2 and N0
•4.2. T2 and N>0
•4.3. T1 and N>0
•4.4. T1 and N0 and grade 3
•5. Within 3 months of first oral adjuvant endocrine therapy (AET) prescription (tamoxifen or aromatase inhibitor)
•6. Completed surgery
•7. Completed chemotherapy (if applicable)
•8. Can access the internet and have an email address
•9. Are willing to use a support package with a web-based component
•Sub-study 2
•The following patients will be eligible:
•1. Aged 18 years old and over
•3. Diagnosis of ER-positive invasive breast cancer
•4. Medium or high risk of recurrence, defined as one of the following:
•4.1. T2 and N0
•4.2. T2 and N>0
•4.3. T1 and N>0
•4.4. T1 and N0 and grade 3
•5. Were first prescribed oral AET (tamoxifen or aromatase inhibitor) within the past 9-36 months
•6. Have completed surgery
•7. Have completed chemotherapy (if applicable)

•Sub-study 1 and 2 exclusion criteria:
•The following patients with early-stage ER+ve invasive breast cancer will be ineligible:
•2. Have been prescribed adjuvant CDK4/6i (abemaciclib)
•3. Have cognitive impairment sufficient to preclude participation, as judged by the clinical team
•4. Are unable to read and understand English
•5. Had previous AET (for another breast cancer)
•6. Have not had surgery for breast cancer

发起方

ewcastle upon Tyne Hospitals NHS Foundation Trust